# David S. Siegel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-s-siegel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,887 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 83 |
| i10-index | 289 |
| Last Known Institution | Hackensack Meridian Health |
| OpenAlex ID | https://openalex.org/A5023752321 |
| ORCID iD | https://orcid.org/0000-0002-3604-2574 |
| Works | 699 |

## Researcher papers

- [Antitumor Activity of Thalidomide in Refractory Multiple Myeloma](https://scholariq.org/papers/antitumor-activity-of-thalidomide-in-refractory-multiple-myeloma/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/anti-bcma-car-t-cell-therapy-bb2121-in-relapsed-or-refractory-multiple-myeloma/)
- [Toxic acute tubular necrosis following treatment with zoledronate (Zometa)](https://scholariq.org/papers/toxic-acute-tubular-necrosis-following-treatment-with-zoledronate-zometa/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Hackensack Meridian Health](https://scholariq.org/institutions/hackensack-meridian-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.